Andrew Guggenhime
Director of Finance/CFO chez VAXCYTE, INC.
Fortune : 7 M $ au 31/05/2023
Profil
Andrew L.
Guggenhime is currently an Independent Director at Caribou Biosciences, Inc. and the President & Chief Financial Officer at Vaxcyte, Inc. He previously served as a Director at CardioDx, Inc. from 2014 to 2016 and as an Independent Director at Metacrine, Inc. from 2018 to 2023.
Andrew also held positions at Wells Fargo & Co. as an Assistant VP-Real Estate Capital Markets Group, Neoforma, Inc. as the Chief Financial Officer & Senior Vice President from 2000 to 2006, Calistoga Pharmaceuticals, Inc. as the Chief Financial Officer from 2010 to 2011, Abbott Biotherapeutics Corp.
as the Chief Financial Officer & Senior Vice President from 2008 to 2010, PDL BioPharma, Inc. as the Chief Financial Officer & Senior Vice President from 2006 to 2008, and Dermira, Inc. as the Chief Financial Officer from 2018 to 2020.
He also worked at Merrill Lynch & Co., Inc. as a Vice President from 1996 to 2000.
Mr. Guggenhime completed his undergraduate degree at Middlebury College and holds an MBA from the Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VAXCYTE, INC.
0,09% | 18/04/2024 | 95 679 ( 0,09% ) | 7 M $ | 31/03/2024 |
METACRINE INC
-.--% | 03/02/2023 | 0 ( -.--% ) | - $ | 31/05/2023 |
| 20/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Andrew Guggenhime
| Sociétés | Poste | Début |
|---|---|---|
| VAXCYTE, INC. | Director of Finance/CFO | 01/05/2020 |
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 01/04/2021 |
Anciens postes connus de Andrew Guggenhime
| Sociétés | Poste | Fin |
|---|---|---|
| METACRINE, INC. | Director/Board Member | 23/03/2023 |
| DERMIRA, INC. | Director of Finance/CFO | 01/05/2020 |
| CARDIODX INC | Director of Finance/CFO | 28/04/2014 |
Calistoga Pharmaceuticals, Inc.
 Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Director of Finance/CFO | 01/04/2011 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Director of Finance/CFO | 01/06/2010 |
Formation de Andrew Guggenhime
| Middlebury College | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| WELLS FARGO & COMPANY | Finance |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| VAXCYTE, INC. | Health Technology |
| METACRINE, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Neoforma, Inc.
 Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | Distribution Services |
CardioDx, Inc.
 CardioDx, Inc. Medical/Nursing ServicesHealth Services CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA. | Health Services |
Calistoga Pharmaceuticals, Inc.
Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
| Merrill Lynch & Co., Inc. | Finance |
